Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.69 |
| ▸ | CA1 | P00915 | 2/20 | 0.69 |
| ▸ | CA2 | P00918 | 2/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ALPL | P05186 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29927370 | 1.00 | CA12 (0.69) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL28304469 | 0.98 | CA12 (0.67) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL26613580 | 0.82 | CA2 (1.00) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL1771001 | 0.81 | CA12 (0.51) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL2377240 | 0.81 | CA12 (0.51) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL2377244 | 0.81 | ALDH1A1 (0.54) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL10296114 | 0.81 | MGAM (0.51) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL29712704 | 0.80 | ALDH1A1 (0.53) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL4668553 | 0.80 | ALDH1A1 (0.53) | CA12CA1CA2CA9CYP1A2 | |
| Hydrochloric Acid SCHEMBL27809967 | 0.80 | MGAM (0.50) | CA12CA1CA2CA9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115397972-A | In vitro poultry food | 优良肉品公司 | 2022-11-25 | — | — | CN | claimed |
| EP-3983529-A1 | IN VITRO AVIAN FOOD PRODUCT | Good Meat, Inc. (US) | 2022-04-20 | — | — | EP | claimed |
| CN-108884046-B | Chemical compounds as inhibitors of kinase activity | 葛兰素史克知识产权开发有限公司 | 2021-11-09 | — | — | CN | claimed |
| US-20200392461-A1 | IN VITRO AVIAN FOOD PRODUCT | AHIMSA FOUNDATION | 2020-12-17 | — | — | US | claimed |
| WO-2020252388-A1 | IN VITRO AVIAN FOOD PRODUCT | JUST, INC. (US) | 2020-12-17 | — | — | WO | claimed |
| CN-110121499-A | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2019-08-13 | — | — | CN | claimed |
| CN-103384662-A | Novel 1, 2-bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN INC | 2013-11-06 | — | — | CN | claimed |
| EP-0757674-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 1997-02-12 | — | — | EP | claimed |
| WO-1995029159-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 1995-11-02 | — | — | WO | claimed |
| US-20260055157-A1 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | NOVARTIS AG (CH) | 2026-02-26 | — | — | US | disclosed |
| CN-118045081-B | Application of settop alcohol in preparing antitumor drug | 中山大学孙逸仙纪念医院 | 2025-04-08 | — | — | CN | disclosed |
| CN-116478129-B | Quinoline compound and use thereof | 深圳默元生物科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2024-12-05 | — | — | US | disclosed |
| CN-113582889-B | Sulfonylureas and related compounds and uses thereof | 昆士兰大学 | 2024-09-20 | — | — | CN | disclosed |
| CN-107428696-A | Sulfonylureas and related compounds and uses thereof | 昆士兰大学 | 2017-12-01 | — | — | CN | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017095751-A1 | COMPOSITIONS AND METHODS FOR MODULATING CANCER CELL METABOLISM | PARTIKULA LLC (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20170042930-A1 | METHOD OF TREATING A DISEASE USING A GLYCOLYTIC DEPENDENT COMPOUND | ETHICON, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2016131098-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-08-25 | — | — | WO | disclosed |
| CN-103384662-A | Novel 1, 2-bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN INC | 2013-11-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | CA12 4653/4885CA1 4141/4885CA2 2434/4885 |
| US-20260055157-A1 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | IL2RA, IL2, ICOS | CA12 314/4885CA1 1377/4885CA2 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.